| 3.85 -0.86 (-18.26%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.73 | 1-year : | 18.68 |
| Resists | First : | 10.9 | Second : | 16 |
| Pivot price | 10.73 |
|||
| Supports | First : | 2.66 | Second : | 2.21 |
| MAs | MA(5) : | 6.05 |
MA(20) : | 10.61 |
| MA(100) : | 10.55 |
MA(250) : | 9.83 |
|
| MACD | MACD : | -1.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 8.3  |
D(3) : | 14.5 |
| RSI | RSI(14): 31.7 |
|||
| 52-week | High : | 16 | Low : | 2.66 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELTX ] has closed above bottom band by 9.7%. Bollinger Bands are 368.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.56 - 4.58 | 4.58 - 4.6 |
| Low: | 3.61 - 3.63 | 3.63 - 3.65 |
| Close: | 3.81 - 3.84 | 3.84 - 3.88 |
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Wed, 17 Jun 2026
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug - Benzinga
Tue, 16 Jun 2026
Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) - PR Newswire
Mon, 15 Jun 2026
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - Yahoo Finance
Mon, 15 Jun 2026
ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc. - GlobeNewswire
Mon, 15 Jun 2026
Elicio nosedives on phase 2 data for pancreatic cancer asset (ELTX:NASDAQ) - Seeking Alpha
Mon, 15 Jun 2026
Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 1.319e+007 (%) |
| Held by Institutions | 29.7 (%) |
| Shares Short | 1,660 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.738e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -92.5 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.01 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 1.9e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|